🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
18.41
+0.41 (2.28%)
Nov 18, 2026, 4:00 PM EST - Market closed
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

AVLAYAH’s launch has completed two successful quarters, with adult label expansion and international access key to growth. Sanfilippo, FTD-GRN and Alzheimer’s programs have important data and development milestones ahead, including several targeted for 2027.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. We're going to get started. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. Thanks for joining me today. It's my pleasure to have the Denali team with me. To my direct right is Ryan Watts, CEO, and to his right is Katie Peng, Chief Commercial Officer, and to her right is Alex Schuth, Chief Operating Officer and Chief Financial Officer. Welcome all of you.

Ryan Watts
CEO, Denali Therapeutics

Yeah, great to be here. Thanks, Andrew.

Alex Schuth
COO and CFO, Denali Therapeutics

Thanks, Andrew.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Yes. Would you mind giving us an overview of Denali, a brief overview? What you're working on, what programs you have, milestones over the next 6-12 months would be helpful to level set everything.

Ryan Watts
CEO, Denali Therapeutics

Yeah, great. Thanks, Andrew. Great to be here in London. Great to be here with Katie and Alex. Looking forward to today's Q&A and questions. It's obviously a very exciting time at Denali over the last year, launching our first product, AVLAYAH, for Hunter syndrome. I think what's been most exciting about the last six months is seeing this product taken up by the community and engaging with the community and some of the, really the case experiences with the medicine and how it's starting to transform life. In fact, that's our goal at Denali, is to use the TransportVehicle to transform life. The way to think about it today is that we now have a product that validates the TransportVehicle. That TransportVehicle is the platform, and that platform can now be applied across a broader pipeline. We have a broad pipeline.

In addition to Hunter syndrome, we have Sanfilippo. Just as we talk about the future, next year we're going to be filing a BLA for Sanfilippo. Again, Enzyme TransportVehicle, using the technology to get across the blood-brain barrier. We also have important readouts in Pompe and FTD-GRN. I think where there's a lot of focus is in our Alzheimer's portfolio, especially with all the exciting data that continues to come out with amyloid approaches and tau approaches, including data just yesterday, for example, at CTAD. If you want to know about that data, just read Andrew's notes. Well done. Basically, it's a very exciting time, and the product platform pipeline is the story for us at Denali. Also, a great launch by Katie and her team.

As we start to generate revenue, that extends our runway, and we're just excited to bring more products forward using the TransportVehicle.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Perfect. Thank you. Maybe to start with the ETV franchise, but starting with Hunter and then Sanfilippo, congratulations on all the great progress. Maybe a big picture for Hunter, can you just remind us how many patients there are in both the U.S. and the ex-U.S.? What is the peak sales potential?

Katie Peng
Chief Commercial Officer, Denali Therapeutics

Sure. We've been really pleased with our launch so far in the U.S. So total U.S. population is about 500 patients, and with the current FDA label, it's 375. So around 75% of the patients are eligible based on the pediatric label. Worldwide, there's about another 1,500 patients, a third outside of Europe and a third in Europe. Overall, we've had really two very successful quarters. As Ryan mentioned, the feedback from the community has been pretty overwhelming. We had just come here from a patient event, and hearing the direct stories from the families on how well patients are doing on AVLAYAH really gives us that momentum going forward. Of course, our desire is to become the market leader in Hunter syndrome, and that is defined as being able to treat all new patients.

Physicians would select AVLAYAH as the top therapy for treating new patients as well as prevalent patients, which is the majority of patients switching from the current ERT treatment to AVLAYAH, and having dominant market share.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Would it be fair to say, because when I think ELAPRASE, the existing, the other approved drug, I view your compound to be superior because it's brain penetrant, you're getting superior biomarker, and so forth. Is it fair if ELAPRASE is doing $700 million worldwide, give or take, you'd get all of that and more?

Katie Peng
Chief Commercial Officer, Denali Therapeutics

Yes. Based on how we're seeing the trajectory of the launch today, we definitely expect that. There's a few things that we need to achieve. One is the expansion of the label into adults. Adults make up 25% of the population, but 30% or more of the value because of their weight. Our product is weight-based dosing. Very important for us to be able to expand into the international markets, and we're doing a lot of work on the regulatory pathways in a third of the markets that don't require our phase III COMPASS study. So that's ongoing as well. As long as we continue to build our base, we feel very confident that we can exceed the current standard of care's revenues worldwide.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Thanks. One more question on the pricing side. You mentioned weight-based dosing. Just to help frame the comparison of your price versus ELAPRASE, what is the annual price on compare How does that compare to ELAPRASE at the same dose?

Katie Peng
Chief Commercial Officer, Denali Therapeutics

Yeah, great. In the U.S., assuming a 30-kg patient, it is about a 60% premium. So our patients are about $800,000 versus $500,000 a year for the current ERT treatment.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Great. The launch is going very well, even better than what I think you guys had internally expected. So it is great. You have guided Q4 to do $30 million-$32 million, and I think that is two full quarters. Come 2027, are you inclined to give more guidance either on a quarterly or annual basis, and when would be the right venue to do so?

Alex Schuth
COO and CFO, Denali Therapeutics

Yeah, I will take that one. We decided for 2026 to provide quarterly revenue guidance because we wanted to give investors the clearest picture about really how the trajectory of the launch is going. We also made it very clear that the guidance would only be for 2026, and at this point, we have not yet disclosed how we will approach 2027.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay, very good. Katie, you mentioned one other lever was the COMPASS data to help you gain more ex-U.S. approvals. Remind us when the COMPASS data, that is your confirmatory study, when that dataset is, and does it open up every ex-U.S. region more or less from there?

Katie Peng
Chief Commercial Officer, Denali Therapeutics

Yes. For COMPASS, I think that will open up adults for us in the U.S., but also for Europe. For the rest of the other countries, a third of the other countries, there are many accelerated pathways, and we can leverage the U.S. CPP to be able to gain regulatory approval. Of course, that is one step in the process outside of the U.S. You need pricing and reimbursement as the second part to follow very quickly in order to gain market access into the countries.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I see.

Ryan Watts
CEO, Denali Therapeutics

In terms of timing, the COMPASS study will complete the two-year endpoint at the end of next year, and then look to 2028 for readout. We have, of course, a sense of urgency because as we think about, as Katie mentioned, the U.S. launch and now the next third, which we are actively pursuing, and the final third, that is going to be key with COMPASS. Just a reminder, 65 patients, there are two cohorts. One focused on the neurologic manifestations, the other actually focused on really somatic or peripheral endpoints, and that one includes adults, so that is going to be key.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I see. What is great is this is a head-to-head study versus ELAPRASE. It is a co-primary endpoint with the HS biomarker that you already have an accelerated approval for, and then you are now looking at Vineland, which is, I think, the cognitive side of things. So what exactly is stat sig on Vineland?

Ryan Watts
CEO, Denali Therapeutics

Yeah. So actually, it is probably worthwhile to just comment. In these diseases, in the childhood diseases, the Vineland is a measure of behavioral endpoints, and Bayley or Kaufman, depending on age, is cognition. As we talk about Sanfilippo, we will talk a little bit more about Bayley. Here we are talking about Vineland, which is, and we are actually looking at a composite where you see improvement in behavior. We see improvement in both Bayley and Vineland. That was published in the New England Journal article earlier this year, leading to obviously the approval. Our assessment of how to power that study is really based on our phase I/II experience, but also natural history data that we were able to obtain, including other studies that were large that failed, but just looking at the totality of the data. It is similar in Sanfilippo.

The existence of some natural history allows us to think about the powering of these studies.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Well, to me, ELAPRASE is not brain penetrant, so it should not do anything on Vineland.

Ryan Watts
CEO, Denali Therapeutics

Yeah. I mean, I think the reality is that you have heterogeneity in patients, so their mutations are different and their progression is different. What you're still looking for is change over time. Just as a reminder, in Hunter syndrome, most patients develop relatively normal to age two or three, and then they start to fall off the developmental curve. Cohort A is focused on ages two to six, which is that critical window where you start to see a real separation.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. The Hunter launch is going very well. It should continue that way. Maybe switching gears to Sanfilippo, I think you have the full dataset at WORLD next year, February of 2027. Big picture, again, what's the peak sales potential of this drug? How many patients in the U.S. and ex-U.S.?

Katie Peng
Chief Commercial Officer, Denali Therapeutics

We estimate that Sanfilippo is similar to Hunter, but there, for the prevalence population, it's harder to gauge exactly that number because there hasn't been any treatment. It's an estimate, but we think the opportunity is very similar to MPS II, and yeah.

Andrew Tsai
Senior Biotech Analyst, Jefferies

You've already shared a cut of the, is it 20 patients total cohort? I just forget, sorry. But you shared already initial cut at the lower doses of the Sanfilippo study, and we're going to get the full dataset at WORLD. Is it fair to assume with the full dataset at WORLD, the efficacy should look even stronger? Maybe talk about what you saw initially.

Ryan Watts
CEO, Denali Therapeutics

You have a lot to remember, Andrew. I do not expect you to remember. We have the first eight patients where we did essentially dose finding, both dose frequency and dose level, and what we learned was actually quite interesting. Probably we should have known this from our experience with Hunter, but more frequent dosing leads to better tolerability, and that is the case for enzyme replacement therapies. As long as you have drug on board, you can build tolerability over time. We saw 80% average reduction in CSF heparan sulfate. This is the best that has ever been shown in this disease, in addition to the ability to normalize heparan sulfate in a subset of these patients. Those that did not normalize had more anti-drug antibodies, which again is very common in ERT therapy. That was the first eight patients.

We then enrolled an additional 12 patients, and the total dataset at WORLD will include all 20 patients, and we pre-specified with the FDA those 12 patients which are on the to-be-marketed dose, including the dose escalation. That is the data that we plan to show at WORLD, which will include CSF heparan sulfate and likely other biomarkers. I should have mentioned that there is a lysosomal biomarker that we showed at WORLD this year where we had six out of seven patients normalize. That was GM3. We see a really robust biological effect, and then that dataset will mature over time while we also begin enrollment of the phase III study, which will be the confirmatory study for the accelerated approval.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I see. 80% + reduction on the CSF biomarker, which I think is the basis, part of the core basis for the accelerated approval. Is there a threshold that-

Ryan Watts
CEO, Denali Therapeutics

Yeah. It is a great question. I mean, obviously the only medicine approved on a biomarker in MPS is AVLAYAH, and there we achieved basically 90% reduction. Very similar robust reduction, the ability to normalize, and so we have set that bar obviously high. The real question I think you are asking is, what level of reduction do you need to drive clinical benefit? And for us, it is what comes downstream of that biomarker, which would be other lysosomal biomarkers, and ultimately neurofilament light chain, which is a marker of neurodegeneration, which of course in the Hunter program we saw over time the ability to normalize. I think you are probably well aware that medicines that actually normalize NfL universally have received approval, and most of them are very impactful in terms of disease modification.

Andrew Tsai
Senior Biotech Analyst, Jefferies

At WORLD, because the initial first set of patients have been followed up for some time now. Are you tracking functional outcomes actually, including Bayley, for instance?

Ryan Watts
CEO, Denali Therapeutics

Yeah, so it is very early. If you actually look at the dataset of the gene therapy was approved, there is a very long-term dataset. For us, it is early. Of course, we are tracking those small patient number. I think one really important point is that if you really look carefully what has been done in Sanfilippo, there are categorically two types of patients. There are those that are really severe, and if you do not capture those really early, they will progress. Then there are those that are less severe, and DQ score is a way of measuring these things. In other programs, there was essentially an intent to treat population that picked either very young or less severe patients. We obviously have now 20 patients, so we will see how that data reads out.

Obviously, the database lock is happening now, and the data analysis is happening now, then WORLD will be where we present that data.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I see. Okay. The confirmatory study you just said is starting up now, or give or take. Unlike the Hunter confirmatory study, where it is head-to-head, here it could be open label. You could take a cut of the data whenever you want. So when would you take a cut?

Ryan Watts
CEO, Denali Therapeutics

Yeah, we've just began. I mean, we have actually recently at SSIEM shared the details of that phase III design. It's actually very different than COMPASS, as you point out, because there's no standard of care. All patients essentially are going to be treated with Zafi in that paradigm. Again, it's similar biomarker, CSF heparan sulfate. Here we're looking at Bayley. Obviously other endpoints, key secondary endpoints like Vineland. We haven't guided on timing because a lot of it will be how we enroll. Obviously, the landscape is shifting as well with the approval of a gene therapy, and so we're taking that into consideration as we enroll this study.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I see. There could be, are you talking to the FDA a little bit more because of Ultragenyx's approval?

Ryan Watts
CEO, Denali Therapeutics

That's correct.

Andrew Tsai
Senior Biotech Analyst, Jefferies

To help inform your design further?

Ryan Watts
CEO, Denali Therapeutics

Right. That was actually one of the, as I think many are aware, that approval was based on essentially looking at natural history as a comparator, which is not very commonly done. In some ways, that bar has shifted in terms of the way we will look at efficacy. Frankly, I think it is great for the field, especially in ultra-rare disease where it is hard to enroll these studies. It gives you flexibility to look at historical datasets. For us, we are comparing to baseline, which is different. We have had a lot of engagement with the FDA, so of course, we are going to be looking for alignment with CDER and CBER as our program goes forward, as that bar is now different based on gene therapy.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Thanks for the update on that. Moving on to your other programs, a whole suite of other data readouts. Maybe first with the progranulin program, I think you have a dataset in first half 2027. For FTD, remind us how big this market opportunity is.

Alex Schuth
COO and CFO, Denali Therapeutics

Yeah, so this program, frontotemporal dementia, our patient population are those that have a mutation in granulin, which is about 6%-10% of the overall FTD population. The mechanism for this drug here is very similar to our mechanism in the ERT portfolio, as it is protein replacement therapy. Patients with this mutation, they lack the progranulin protein, which is a lysosomal protein, and we essentially substitute that protein. We had recently made the decision to extend the treatment duration from six months to 12 months, and this is really intended to give us the best chance of success with respect to measuring proximal and distal biomarkers. So proximal markers are those that directly measure lysosomal function, like glucosylsphingosine. Distal markers, again, is neurofilament, the strongest predictor of neuronal health. As we know from our experience in the enzyme field, that neurofilament movement takes time.

We had seen in our Hunter syndrome program a significant decline starting at six months and then pronounced at one year, and therefore we extended the treatment duration.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay, that's great, and that's very strategic. On NfL then, what percent reduction on NfL would make you inclined to file for accelerated approval?

Alex Schuth
COO and CFO, Denali Therapeutics

Yeah, that is a great question. There is not a great answer to this. I think in the end, it has to be a believable reduction. With respect to NfL, there is precedent in several indications. FTD is really on the spectrum of ALS and FTD, and specifically in ALS with tofersen, there is the precedent that tofersen was approved through the accelerated approval pathway on NfL reduction, which was then a strong predictor of clinical benefit down the road. So our approach here is we will look at the totality of the data after the study reads out, and then we will then seek the conversation with the FDA about a potential accelerated approval pathway.

Andrew Tsai
Senior Biotech Analyst, Jefferies

If there was no accelerated approval, as you're talking to the FDA, do you design a confirmatory study in the meantime just to ensure you don't lose time?

Alex Schuth
COO and CFO, Denali Therapeutics

Yeah. It's a good question. Of course, we are scenario planning for the future, but I think step one is really to look at all the data collectively and then decide on the progress of the program.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Great. That is first half. Shifting to your Alzheimer's programs, you have a tau Aβ program, like you said, Ryan, datasets in 2027. Maybe starting with the overall differentiation for both programs, would you mind letting us know how you are differentiated from the current therapies approved and emerging in the pipeline?

Ryan Watts
CEO, Denali Therapeutics

Yeah. I mean, we are 25 minutes into the fireside chat, and we finally make it to Alzheimer's, which of course is some of our biggest programs, and one of the main reasons we founded Denali is to really go after Alzheimer's disease using the TransportVehicle technology. What an extraordinary time. We have now one validated target, and I think with the extended, all caveats considered again, with the extended dataset for the ASO, intrathecally delivered ASO, BIIB080, there is probably a second validated target in Alzheimer's disease, which is really exciting. So we set out to basically find a way to approach knocking down tau and also removing amyloid plaque using the TransportVehicle. What we have is the advantage of two decades of data in front of us to be able to engineer the TransportVehicle uniquely.

Starting first with tau, we are using the TransportVehicle to give an even distribution throughout the brain, which is very different than intrathecal. Sorry, we give IV, we use the TransportVehicle, and you get this even distribution. There we are targeting robust knockdown in CSF. What we will assume, which we learned from AVLAYAH, because many of you may recall that ELAPRASE was also delivered intrathecally. They saw reduction in biomarker, but they did not see necessary clinical benefit, and they did not see neurofilament light chain reduced. Part of that is because there is an uneven distribution when you inject a molecule into the spine and look for even basically knockdown or uptake throughout the entire central nervous system. So here we expect when we measure CSF, we are actually measuring what is happening across the entire brain. That will be the key.

Next year we are looking at CSF tau and identifying the right dose. Once we have that dose, then obviously on the data that we have just seen with BIIB080, I think moving forward to efficacy studies would be the way to go. In terms of Aβ, we have a uniquely engineered antibody that is essentially, I will call it an on-off switch. So when bound to transferrin receptor, you do not engage the immune system, and as a result, you do not have an effect on reticulocytes. Hematology has been one of the challenges with the competitor molecule, as well as immunogenicity and tolerability. So I think we would still see a lot of IRRs with that molecule.

Our goal here is that without having the sort of appended shuttle, but rather using the TransportVehicle that has the integrated TfR binding, we look for better tolerability, better hematological findings, and also that even distribution and plaque reduction. Also, I think a really key goal here is subcu dosing, so that's what we imagine will be the future for these medicines. Really a prevention setting. You have early plaque deposition, no cognitive decline, you take a subcu dose and you remove plaque safely, and that's the goal of DNL921.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Oh, great. Maybe one question on tau, because I think the first dataset is actually going to be an actual Alzheimer's patient.

Ryan Watts
CEO, Denali Therapeutics

That's right.

Andrew Tsai
Senior Biotech Analyst, Jefferies

What kind of tau reduction is best after the Biogen dataset that we've seen?

Ryan Watts
CEO, Denali Therapeutics

Yeah, I mean, it's a great question. I go back to the fact that the biodistribution is quite different for intrathecal versus a BBB-enabled. If you take at face value the tau data so far, it would be 45% or less, in fact, because you have this uneven distribution. When you're measuring tau in the same area that you inject the ASO, probably the most tau reduction is going to be in the region where you do. We saw that obviously in Hunter syndrome, that the most reduction in heparan sulfate was in the region where the enzyme was injected. I think that sets the bar probably somewhere between 20% to maybe 50%.

Interestingly, I think there's a lot. The data is now, at least what we're seeing and what you wrote about, Andrew, is the low dose is what Biogen is moving forward with. I don't know if we can use that as our own bar with the BBB technology, but it's not going to be a lot of tau reduction that's driving that clinical benefit if you'd also consider the uneven distribution.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Right. That makes a lot of sense.

Ryan Watts
CEO, Denali Therapeutics

Also, just to add one point, you're right that we are going in Alzheimer's patients first, so that's great. We went straight to Alzheimer's, multi-dose. That allows us to look at what are we seeing in terms of tau reduction, then bringing this whole portfolio of Alzheimer's medicines forward with the TransportVehicle.

Andrew Tsai
Senior Biotech Analyst, Jefferies

For the Aβ program, my understanding is it is going to be initially in healthies, looking at reticulocytes, a precursor for anemia. My question is actually, when do we get the MAD data in actual Alzheimer's patients? Is that a 2027 event?

Ryan Watts
CEO, Denali Therapeutics

Yeah, so we are going back to this idea of the on-off switch for DNL921. The healthy volunteer allows us to assess off, meaning what does the hematology look like if the cisLALA mutation is actually silencing the antibody when bound to transferrin receptor? We know that in healthy volunteers. So that is important question number one. The on, meaning the ability to reduce plaque, will be in Alzheimer's patients. Our goal is to have early biomarker data in 2027 for plaque reduction as well. It is great to be able to know, like, did you engineer the molecule the right way? Which is unique from what others have done. One other comment with the TransportVehicle, because you have this integrated TfR binding, all the conventional Fab approaches use these linkers, and our experience has been that after 24 hours, many of those molecules do not maintain the stability.

Therefore, our brain uptake is superior, and I think importantly, probably tolerability is related to those sort of unique architectures versus an integrated TfR binding.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I see. So far, for your programs, I think we are talking about the IV. You mentioned earlier you definitely want to pursue subcu. When exactly does that happen? Is it after these initial data?

Ryan Watts
CEO, Denali Therapeutics

Yeah, I would just say stay tuned. Major focus. Major focus to have subcu.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay.

Ryan Watts
CEO, Denali Therapeutics

Yeah.

Andrew Tsai
Senior Biotech Analyst, Jefferies

I think maybe we wrap it up here then because I do not know if we have time for Pompe, also [inaudible] . Bottom line is you are executing, the pipeline is growing, lots of datasets coming up over the next year, and value inflection period. Yeah.

Ryan Watts
CEO, Denali Therapeutics

Yeah. Thank you, Andrew. Obviously great year this year. Looking forward to lots of data next year. Thank you.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Thank you.